|Support type:||Scholarships in Brazil - Doctorate|
|Effective date (Start):||September 01, 2011|
|Effective date (End):||November 30, 2014|
|Field of knowledge:||Biological Sciences - Pharmacology - General Pharmacology|
|Principal researcher:||Sandra Helena Poliselli Farsky|
|Grantee:||Ana Lucia Borges Shimada|
|Home Institution:||Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
Diabetes (DM) currently affects 285 million people worldwide. In 2030, an estimated 428 million people will have this disease (IDF, 2010). Since the literature reports a possible association between diabetes and exposure to persistent organic pollutants (POPs) such as polychlorinated biphenyls (PCBs), this project aims to investigate whether exposure to PCB no. 126 triggers endogenous alterations involved in the pathogenesis of type II diabetes. For this purpose, male Wistar rats will be exposed by instillation to the PCB126 1 or 10 ppb (1 or 10 mg/L). Animals exposed to vehicle will be used as a control. Twenty-four hours following the last exposure, animals will be killed for collection of circulating blood and pancreas. In blood samples, will be evaluated: the number of circulating cells, the expression of adhesion molecules in circulating leukocytes by flow cytometry, the plasma levels of circulating adhesion molecules of endothelial activity and the concentration of proinflammatory such IL-1beta, TNF-alpha and IL-6 by ELISA and NO by Griess reaction, biochemical and lipid profile, the insulin levels and basal and glucose tolerance test. In pancreatic tissue samples, will be assessed: the pancreatic islets purity, viability and morphology; the myeloperoxidase activity (MPO); the stereology; proteomics for the profile of inflammatory proteins; the expression of AhR and PPAR receptors; the intravital miscroscopy; and leukocyte-endothelial interactions analysis. The results may contribute to the elucidation of the effects caused by PCBs exposure, possibly on observed changes during the development of type II diabetes.